Affiliation:
1. Union Hospital, Huazhong University of Science and Technology
2. People’s hospital, Mongolian Autonomous prefecture of Bortala
Abstract
Abstract
Background: The aim of this study was to investigate the effect of Sacubitril/valsartan (Sac/Val) in patients diagnosed with nonvalvular atrial fibrillation (AF) without systolic heart failure (SHF).
Methods: Nonvalvular AF patients without SHF admitted to the People’s Hospital of Boltala Mongolian Autonomous Prefecture from December 2020 to December 2021 were enrolled and randomly divided into the Sac/Val treatment group (group T) and valsartan treatment group (group C, control). For subgroup analysis, patients were divided into subgroups with and without diastolic heart failure (DHF). After a 1-month run-in period and subsequent 3-month treatment period, patients were followed up in the cardiology clinic. Plasma levels of biochemical markers and echocardiographic parameters before and after treatment were compared, and DHF scores were calculated for comparison of diastolic function.
Results: Of 61 enrolled patients, 46 patients completed the follow-up. Sac/Val treatment did not increase the proportion of sinus rhythm. Although NT-proBNP expression tended to be reduced in both groups after 3 months of treatment, the differences compared with respective baseline levels and between groups were not significant. Subgroup analysis suggested that NT-proBNP expression in the subgroup with DHF was decreased at follow-up versus baseline, but the difference was not significant. Similarly, no marked differences in echocardiographic parameters or tissue Doppler parameters related to DHF were detected between the groups (P>0.05). Subgroup analysis also showed no significant differences in the echocardiographic parameters between subgroups (P>0.05).
Conclusion: Sac/Val is not superior to valsartan in the treatment for patients suffering with AF without SHF.
Publisher
Research Square Platform LLC